11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Children with febrile neutropenia commonly exhibit alterations of pharmacokinetic (PK) parameters, leading to decreased β‐lactam concentrations.

          Aims

          This study evaluated piperacillin PK and probability of target attainment (PTA) with continuous infusion of piperacillin‐tazobactam, in order to optimize the dosing regimen.

          Methods

          This prospective PK study included children with cancer, aged 1–17 years, who were treated with piperacillin‐tazobactam for suspected or verified infection. A piperacillin‐tazobactam loading dose (100 mg/kg) was administered followed by continuous infusion (300 mg/kg/day). The unbound fraction of piperacillin was quantified by high‐performance liquid chromatography and PK were described using population PK modeling. PK data was used to update and extend a previous PK model built on data following intermittent administration. Monte Carlo simulations were performed to assess PTA for targets of 100% time above the minimum inhibitory concentration (100% fT > MIC) and 50% fT > 4xMIC.

          Results

          We included 68 fever episodes among 38 children with a median (IQR) age of 6.5 years and body weight of 27.4 kg (15.1–54.0). A three‐compartment model adequately described the concentration‐time data. Median (95% confidence interval) estimates for clearance and piperacillin concentration at steady state were 14.2 L/h/70 kg (13.0; 15.3) and 47.6 mg/L (17.2; 129.5), respectively. Body weight or lean body weight was significantly associated with the PK parameters, and body weight was integrated in the final PK model. Based on piperacillin exposure, continuous infusion was the only dosing regimen to achieve optimal PTA for the P. aeruginosa breakpoint (16 mg/L) with the target of 100% fT > MIC, and a daily dose of 300 mg/kg reached optimal PTA. The strict target of 50% fT > 4xMIC (64 mg/L) was not feasibly attained by any dosing regimen at recommended doses.

          Conclusion

          Unlike conventional piperacillin intermittent administration and extended infusion regimens, continuous infusion allows the target of 100% fT > MIC to be reached for children with febrile neutropenia.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: not found
          • Article: not found

          Developmental pharmacology--drug disposition, action, and therapy in infants and children.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

            Several software tools are available that facilitate the use of the NONMEM software and extend its functionality. This tutorial shows how three commonly used and freely available tools, Pirana, PsN, and Xpose, form a tightly integrated workbench for modeling and simulation with NONMEM. During the tutorial, we provide some guidance on what diagnostics we consider most useful in pharmacokinetic model development and how to construct them using these tools.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.

              Purpose To update a clinical practice guideline (CPG) for the empirical management of fever and neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients. Methods The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate. For questions of risk stratification and evaluation, we updated systematic reviews of observational studies. For questions of therapy, we conducted a systematic review of randomized trials of any intervention applied for the empirical management of pediatric FN. The Grading of Recommendation Assessment, Development and Evaluation approach was used to make strong or weak recommendations and to classify levels of evidence as high, moderate, low, or very low. Results Recommendations related to initial presentation, ongoing management, and empirical antifungal therapy of pediatric FN were reviewed; the most substantial changes were related to empirical antifungal therapy. Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN. Conclusion Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation. Future work should focus on closing research gaps and on identifying ways to facilitate implementation and adaptation.
                Bookmark

                Author and article information

                Contributors
                sabine.froelich@midt.rm.dk
                Journal
                Cancer Rep (Hoboken)
                Cancer Rep (Hoboken)
                10.1002/(ISSN)2573-8348
                CNR2
                Cancer Reports
                John Wiley and Sons Inc. (Hoboken )
                2573-8348
                18 November 2021
                October 2022
                : 5
                : 10 ( doiID: 10.1002/cnr2.v5.10 )
                : e1585
                Affiliations
                [ 1 ] Department of Pediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark
                [ 2 ] Department of Pharmacy Uppsala University Uppsala Sweden
                [ 3 ] Department of Clinical Microbiology Aarhus University Hospital Aarhus Denmark
                Author notes
                [*] [* ] Correspondence

                Sabine F. Maarbjerg, Department of Pediatrics and Adolescent Medicine, Aarhus University hospital, Palle Juul‐Jensens Boulevard 99, DK‐8200 Aarhus N, Denmark.

                Email: sabine.froelich@ 123456midt.rm.dk

                Author information
                https://orcid.org/0000-0001-6244-5871
                Article
                CNR21585
                10.1002/cnr2.1585
                9575485
                34796702
                8ac051cd-9dde-487f-8bf6-7673bb6aca10
                © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 02 September 2021
                : 30 June 2021
                : 25 October 2021
                Page count
                Figures: 3, Tables: 3, Pages: 11, Words: 7956
                Funding
                Funded by: Børnecancerfonden , doi 10.13039/100010733;
                Award ID: 2017‐2003
                Funded by: Holms legacy trust
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                October 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:17.10.2022

                continuous infusion,dose optimization,febrile neutropenia,pharmacokinetics,piperacillin,target attainment

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content281

                Cited by2

                Most referenced authors606